Biohaven (NYSE:BHVN) Trading Down 7.4% – Here’s What Happened

Biohaven Ltd. (NYSE:BHVN)’s share price traded down 7.4% during mid-day trading on Thursday . The stock traded as low as $15.50 and last traded at $15.7030. Approximately 699,601 shares were traded during trading, a decline of 73% from the average session volume of 2,627,393 shares. The stock had previously closed at $16.95.

More Biohaven News

Here are the key news stories impacting Biohaven this week:

• Positive Sentiment: SK Biopharmaceuticals licensing deal: Biohaven granted SK Biopharmaceuticals global rights to its Kv7 ion-channel platform, including opakalim, its lead candidate for focal epilepsy. The agreement provides for upfront and milestone payments totaling up to $795 million, plus tiered royalties ranging from the mid-teens to low twenties on U.S. net sales of opakalim. Reuters article
• Positive Sentiment: Validation of epilepsy platform: Opakalim is in Phase 2/3 development, with topline RISE3 trial results expected in the second half of 2026. The partnership gives Biohaven a global development and commercial partner while preserving potential royalty income. Biohaven and SK Biopharmaceuticals licensing announcement
• Positive Sentiment: Favorable trade-secret ruling: A federal court formally confirmed that RA Capital and Avilar Therapeutics willfully and maliciously misappropriated a Yale-developed trade secret, resulting in a $4 million award to Biohaven and Yale. The ruling provides a legal and financial benefit, although it is considerably smaller than the potential licensing proceeds. Federal court trade-secret judgment
• Neutral Sentiment: Upcoming data remains a key catalyst: Investors are now focused on the RISE3 epilepsy readout and the company’s upcoming obesity-trial results. Positive data could support further gains, while delays or disappointing results could increase volatility. BHVN market reaction and upcoming trial readouts
• Negative Sentiment: Milestone-dependent economics: The headline $795 million amount is a maximum potential value rather than guaranteed near-term revenue. Biohaven must still achieve clinical and regulatory milestones, leaving execution and trial risk in the stock’s valuation. The Pharma Letter licensing coverage

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Needham & Company LLC set a $11.00 price objective on Biohaven in a report on Monday, June 29th. Wall Street Zen raised shares of Biohaven from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 27th. HC Wainwright reissued a “neutral” rating on shares of Biohaven in a research report on Thursday. TD Cowen restated a “buy” rating on shares of Biohaven in a research note on Wednesday. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Biohaven in a report on Tuesday, June 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, four have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $18.94.

Biohaven Stock Performance

The company has a debt-to-equity ratio of 21.23, a quick ratio of 4.73 and a current ratio of 4.73. The company has a market cap of $2.40 billion, a P/E ratio of -3.37 and a beta of 1.26. The firm has a 50 day moving average price of $14.74 and a 200-day moving average price of $11.83.

Biohaven (NYSE:BHVN) last posted its earnings results on Monday, August 10th. The company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.15). On average, research analysts predict that Biohaven Ltd. will post -3.29 EPS for the current year.

Hedge Funds Weigh In On Biohaven

A number of institutional investors have recently modified their holdings of BHVN. AQR Capital Management LLC boosted its holdings in shares of Biohaven by 49.4% during the 1st quarter. AQR Capital Management LLC now owns 114,849 shares of the company’s stock worth $2,761,000 after buying an additional 37,981 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Biohaven by 32.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 71,833 shares of the company’s stock worth $1,747,000 after acquiring an additional 17,562 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Biohaven by 7.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 589,615 shares of the company’s stock valued at $14,174,000 after acquiring an additional 41,040 shares during the period. Intech Investment Management LLC boosted its holdings in Biohaven by 80.3% during the first quarter. Intech Investment Management LLC now owns 61,598 shares of the company’s stock valued at $1,481,000 after acquiring an additional 27,433 shares during the period. Finally, Quantbot Technologies LP boosted its holdings in Biohaven by 1,097.8% during the second quarter. Quantbot Technologies LP now owns 8,840 shares of the company’s stock valued at $125,000 after acquiring an additional 8,102 shares during the period. Institutional investors own 88.78% of the company’s stock.

Biohaven Company Profile

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.